
|Videos|January 21, 2015
Dr. Scott Rowley on Allogeneic Stem Cell Transplant
Author(s)Scott Rowley, MD
Scott Rowley, MD, the Chief of John Theurer Cancer Center's Blood and Marrow Stem Cell Transplantation Division, discusses the challenges of allogeneic stem cell transplant.
Advertisement
Scott Rowley, MD, the Chief of John Theurer Cancer Center’s Blood and Marrow Stem Cell Transplantation Division, discusses the challenges of allogeneic stem cell transplant.
Many allogeneic transplant candidates have resistant disease or comorbidities​ due to previous treatments. This has resulted in a push for creating reduced or less toxic regimens.
The biggest challenge in allogeneic transplant is post-transplant relapse. A primary area of focus in the transplant community is to find novel agents or regimens to reduce risk of relapse, says Rowley.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
5






























































